A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Clinical trial NCT04246086 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04246086
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-12
- Primary completion
- 2030-09-06
- Enrollment
- 237
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.